The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China ...

To help researchers work towards these goals, Illumina has devised two methods for sequencing SARS-CoV-2 from clinical samples: one workflow based on shotgun metagenomics, and one on target ...

Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing ...

(RTTNews) - Illumina, Inc. (ILMN) responded on Monday to the notice from the China Ministry of Commerce stating that it is not permitted to export sequencing instruments into China. Illumina said ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...